tetano
Editor, Senior Moderator
Int J Infect Dis
. 2022 Jul 14;S1201-9712(22)00427-1.
doi: 10.1016/j.ijid.2022.07.033. Online ahead of print.
Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: A multi-centric hospital-based case-control study
Tarun Bhatnagar[SUP] 1 [/SUP], Sirshendu Chaudhuri[SUP] 1 [/SUP], Manickam Ponnaiah[SUP] 1 [/SUP], Pragya D Yadav[SUP] 2 [/SUP], R Sabarinathan[SUP] 1 [/SUP], Rima R Sahay[SUP] 2 [/SUP], Faheem Ahmed[SUP] 3 [/SUP], S Aswathy[SUP] 4 [/SUP], Pankaj Bhardwaj[SUP] 5 [/SUP], Anil Bilimale[SUP] 6 [/SUP], M Santhosh Kumar[SUP] 1 [/SUP], M Logaraj[SUP] 7 [/SUP], Uday Narlawar[SUP] 8 [/SUP], C Palanivel[SUP] 9 [/SUP], Prakash Patel[SUP] 10 [/SUP], Sanjay K Rai[SUP] 11 [/SUP], Vartika Saxena[SUP] 12 [/SUP], Arvind Singh[SUP] 13 [/SUP], Jeromie Wv Thangaraj[SUP] 1 [/SUP], Ashwini Agarwal[SUP] 5 [/SUP], Yasir Alvi[SUP] 3 [/SUP], Amoghashree[SUP] 6 [/SUP], P Ashok[SUP] 6 [/SUP], Dinesh Babu[SUP] 9 [/SUP], Yogesh Bahurupi[SUP] 12 [/SUP], Sangita Bhalavi[SUP] 8 [/SUP], Priyamadhaba Behera[SUP] 13 [/SUP], Priyanka Pandit Biswas[SUP] 2 [/SUP], Jaykaran Charan[SUP] 5 [/SUP], Nishant Kumar Chauhan[SUP] 5 [/SUP], K B Chetak[SUP] 6 [/SUP], Lalit Dar[SUP] 11 [/SUP], Ayan Das[SUP] 3 [/SUP], R Deepashree[SUP] 6 [/SUP], Minakshi Dhar[SUP] 12 [/SUP], Rahul Dhodapkar[SUP] 9 [/SUP], T S Dipu[SUP] 4 [/SUP], Mridu Dudeja[SUP] 3 [/SUP], Manisha Dudhmal[SUP] 2 [/SUP], Ravisekhar Gadepalli[SUP] 5 [/SUP], Mahendra Kumar Garg[SUP] 5 [/SUP], A V Gayathri[SUP] 4 [/SUP], Akhil Dhanesh Goel[SUP] 5 [/SUP], H Basavana Gowdappa[SUP] 6 [/SUP], Randeep Guleria[SUP] 11 [/SUP], Manoj Kumar Gupta[SUP] 5 [/SUP], Farzana Islam[SUP] 3 [/SUP], Mannu Jain[SUP] 10 [/SUP], Vineet Jain[SUP] 3 [/SUP], M Lanord Stanley Jawahar[SUP] 7 [/SUP], Rajendra Joshi[SUP] 10 [/SUP], Shashi Kant[SUP] 11 [/SUP], Sitanshu Sekhar Kar[SUP] 9 [/SUP], Deepjyoti Kalita[SUP] 12 [/SUP], Meenakshi Khapre[SUP] 12 [/SUP], Satyendra Khichar[SUP] 5 [/SUP], Sarika Prabhakar Kombade[SUP] 5 [/SUP], Sunil Kohli[SUP] 3 [/SUP], Abhinendra Kumar[SUP] 2 [/SUP], Anil Kumar[SUP] 4 [/SUP], Deepak Kumar[SUP] 5 [/SUP], Kiran G Kulirankal[SUP] 4 [/SUP], K V Leela[SUP] 7 [/SUP], Triparna Majumdar[SUP] 2 [/SUP], Baijayantimala Mishra[SUP] 13 [/SUP], Puneet Misra[SUP] 11 [/SUP], Sanjeev Misra[SUP] 5 [/SUP], Prasanta Raghab Mohapatra[SUP] 13 [/SUP], M Narayana Murthy[SUP] 6 [/SUP], Dimpal A Nyayanit[SUP] 2 [/SUP], Manish Patel[SUP] 10 [/SUP], Monika Pathania[SUP] 12 [/SUP], Savita Patil[SUP] 2 [/SUP], Binod Kumar Patro[SUP] 13 [/SUP], Ramniwas[SUP] 5 [/SUP], Pragati Rathod[SUP] 8 [/SUP], Naimesh Shah[SUP] 10 [/SUP], Anita Shete[SUP] 2 [/SUP], Deepak Shukla[SUP] 10 [/SUP], M Shwethashree[SUP] 6 [/SUP], Smita Sinha[SUP] 12 [/SUP], Ashish Surana[SUP] 10 [/SUP], Anjan Trikha[SUP] 11 [/SUP], A Tejashree[SUP] 6 [/SUP], Mahalingam Venkateshan[SUP] 13 [/SUP], G Vijaykrishnan[SUP] 7 [/SUP], Sarita Wadhava[SUP] 8 [/SUP], Naveet Wig[SUP] 11 [/SUP], Nivedita Gupta[SUP] 14 [/SUP], Priya Abraham[SUP] 2 [/SUP], Manoj V Murhekar[SUP] 15 [/SUP]
Affiliations
Abstract
Background: India introduced BBV152/Covaxin and AZD1222/Covishield vaccines from January 2021. We estimated effectiveness of these vaccines against severe Coronavirus disease 2019 (COVID-19) among individuals aged ≥45 years.
Methods: We did a multi-centric, hospital-based, case-control study between May and July 2021. Cases were severe COVID-19 patients and controls were COVID-19 negative individuals from 11 hospitals. Vaccine effectiveness (VE) was estimated for full (2 doses ≥14days) and partial (1 dose ≥21 days) vaccination; duration between two vaccine doses and against the Delta variant. We used a random effects logistic regression model to calculate adjusted odds ratios (aOR) with 95% CI after adjusting for relevant known confounders.
Results: We enrolled 1,143 cases and 2,541 controls. The VE of full vaccination was 85% (95% CI: 79%-89%) with AZD1222/Covishield and 71% (95% CI: 57%-81%) with BBV152/Covaxin. The VE was highest for an interval of 6-8 weeks between two doses of AZD1222/Covishield (94%, 95% CI: 86%-97%) and BBV152/Covaxin (93%, 95% CI: 34%-99%). The VE estimates were similar against the Delta strain and sub-lineages.
Conclusion: BBV152/Covaxin and AZD1222/Covishield were effective against severe COVID-19 among the Indian population during the period of dominance of highly transmissible Delta variant in second wave of pandemic. An escalation of two-dose coverage with COVID-19 vaccines is critical to reduce severe COVID-19 and further mitigate the pandemic in the country.
Keywords: AZD1222/Covishield, Delta variant, effectiveness, India; BBV152/Covaxin; COVID-19 vaccines.
. 2022 Jul 14;S1201-9712(22)00427-1.
doi: 10.1016/j.ijid.2022.07.033. Online ahead of print.
Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: A multi-centric hospital-based case-control study
Tarun Bhatnagar[SUP] 1 [/SUP], Sirshendu Chaudhuri[SUP] 1 [/SUP], Manickam Ponnaiah[SUP] 1 [/SUP], Pragya D Yadav[SUP] 2 [/SUP], R Sabarinathan[SUP] 1 [/SUP], Rima R Sahay[SUP] 2 [/SUP], Faheem Ahmed[SUP] 3 [/SUP], S Aswathy[SUP] 4 [/SUP], Pankaj Bhardwaj[SUP] 5 [/SUP], Anil Bilimale[SUP] 6 [/SUP], M Santhosh Kumar[SUP] 1 [/SUP], M Logaraj[SUP] 7 [/SUP], Uday Narlawar[SUP] 8 [/SUP], C Palanivel[SUP] 9 [/SUP], Prakash Patel[SUP] 10 [/SUP], Sanjay K Rai[SUP] 11 [/SUP], Vartika Saxena[SUP] 12 [/SUP], Arvind Singh[SUP] 13 [/SUP], Jeromie Wv Thangaraj[SUP] 1 [/SUP], Ashwini Agarwal[SUP] 5 [/SUP], Yasir Alvi[SUP] 3 [/SUP], Amoghashree[SUP] 6 [/SUP], P Ashok[SUP] 6 [/SUP], Dinesh Babu[SUP] 9 [/SUP], Yogesh Bahurupi[SUP] 12 [/SUP], Sangita Bhalavi[SUP] 8 [/SUP], Priyamadhaba Behera[SUP] 13 [/SUP], Priyanka Pandit Biswas[SUP] 2 [/SUP], Jaykaran Charan[SUP] 5 [/SUP], Nishant Kumar Chauhan[SUP] 5 [/SUP], K B Chetak[SUP] 6 [/SUP], Lalit Dar[SUP] 11 [/SUP], Ayan Das[SUP] 3 [/SUP], R Deepashree[SUP] 6 [/SUP], Minakshi Dhar[SUP] 12 [/SUP], Rahul Dhodapkar[SUP] 9 [/SUP], T S Dipu[SUP] 4 [/SUP], Mridu Dudeja[SUP] 3 [/SUP], Manisha Dudhmal[SUP] 2 [/SUP], Ravisekhar Gadepalli[SUP] 5 [/SUP], Mahendra Kumar Garg[SUP] 5 [/SUP], A V Gayathri[SUP] 4 [/SUP], Akhil Dhanesh Goel[SUP] 5 [/SUP], H Basavana Gowdappa[SUP] 6 [/SUP], Randeep Guleria[SUP] 11 [/SUP], Manoj Kumar Gupta[SUP] 5 [/SUP], Farzana Islam[SUP] 3 [/SUP], Mannu Jain[SUP] 10 [/SUP], Vineet Jain[SUP] 3 [/SUP], M Lanord Stanley Jawahar[SUP] 7 [/SUP], Rajendra Joshi[SUP] 10 [/SUP], Shashi Kant[SUP] 11 [/SUP], Sitanshu Sekhar Kar[SUP] 9 [/SUP], Deepjyoti Kalita[SUP] 12 [/SUP], Meenakshi Khapre[SUP] 12 [/SUP], Satyendra Khichar[SUP] 5 [/SUP], Sarika Prabhakar Kombade[SUP] 5 [/SUP], Sunil Kohli[SUP] 3 [/SUP], Abhinendra Kumar[SUP] 2 [/SUP], Anil Kumar[SUP] 4 [/SUP], Deepak Kumar[SUP] 5 [/SUP], Kiran G Kulirankal[SUP] 4 [/SUP], K V Leela[SUP] 7 [/SUP], Triparna Majumdar[SUP] 2 [/SUP], Baijayantimala Mishra[SUP] 13 [/SUP], Puneet Misra[SUP] 11 [/SUP], Sanjeev Misra[SUP] 5 [/SUP], Prasanta Raghab Mohapatra[SUP] 13 [/SUP], M Narayana Murthy[SUP] 6 [/SUP], Dimpal A Nyayanit[SUP] 2 [/SUP], Manish Patel[SUP] 10 [/SUP], Monika Pathania[SUP] 12 [/SUP], Savita Patil[SUP] 2 [/SUP], Binod Kumar Patro[SUP] 13 [/SUP], Ramniwas[SUP] 5 [/SUP], Pragati Rathod[SUP] 8 [/SUP], Naimesh Shah[SUP] 10 [/SUP], Anita Shete[SUP] 2 [/SUP], Deepak Shukla[SUP] 10 [/SUP], M Shwethashree[SUP] 6 [/SUP], Smita Sinha[SUP] 12 [/SUP], Ashish Surana[SUP] 10 [/SUP], Anjan Trikha[SUP] 11 [/SUP], A Tejashree[SUP] 6 [/SUP], Mahalingam Venkateshan[SUP] 13 [/SUP], G Vijaykrishnan[SUP] 7 [/SUP], Sarita Wadhava[SUP] 8 [/SUP], Naveet Wig[SUP] 11 [/SUP], Nivedita Gupta[SUP] 14 [/SUP], Priya Abraham[SUP] 2 [/SUP], Manoj V Murhekar[SUP] 15 [/SUP]
Affiliations
- PMID: 35843496
- DOI: 10.1016/j.ijid.2022.07.033
Abstract
Background: India introduced BBV152/Covaxin and AZD1222/Covishield vaccines from January 2021. We estimated effectiveness of these vaccines against severe Coronavirus disease 2019 (COVID-19) among individuals aged ≥45 years.
Methods: We did a multi-centric, hospital-based, case-control study between May and July 2021. Cases were severe COVID-19 patients and controls were COVID-19 negative individuals from 11 hospitals. Vaccine effectiveness (VE) was estimated for full (2 doses ≥14days) and partial (1 dose ≥21 days) vaccination; duration between two vaccine doses and against the Delta variant. We used a random effects logistic regression model to calculate adjusted odds ratios (aOR) with 95% CI after adjusting for relevant known confounders.
Results: We enrolled 1,143 cases and 2,541 controls. The VE of full vaccination was 85% (95% CI: 79%-89%) with AZD1222/Covishield and 71% (95% CI: 57%-81%) with BBV152/Covaxin. The VE was highest for an interval of 6-8 weeks between two doses of AZD1222/Covishield (94%, 95% CI: 86%-97%) and BBV152/Covaxin (93%, 95% CI: 34%-99%). The VE estimates were similar against the Delta strain and sub-lineages.
Conclusion: BBV152/Covaxin and AZD1222/Covishield were effective against severe COVID-19 among the Indian population during the period of dominance of highly transmissible Delta variant in second wave of pandemic. An escalation of two-dose coverage with COVID-19 vaccines is critical to reduce severe COVID-19 and further mitigate the pandemic in the country.
Keywords: AZD1222/Covishield, Delta variant, effectiveness, India; BBV152/Covaxin; COVID-19 vaccines.